Revance Therapeutics Inc (RVNC)
3.29
-0.28
(-7.84%)
USD |
NASDAQ |
Apr 25, 09:58
Revance Therapeutics Debt to Equity Ratio: -2.830 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | -2.830 |
| September 30, 2023 | -4.033 |
| June 30, 2023 | 14.20 |
| March 31, 2023 | -14.24 |
| December 31, 2022 | 30.11 |
| September 30, 2022 | 2.600 |
| June 30, 2022 | -143.82 |
| March 31, 2022 | 14.80 |
| December 31, 2021 | 4.099 |
| September 30, 2021 | 2.333 |
| June 30, 2021 | 1.504 |
| March 31, 2021 | 1.145 |
| December 31, 2020 | 0.4823 |
| September 30, 2020 | 0.4757 |
| June 30, 2020 | 0.6816 |
| March 31, 2020 | 0.5555 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.0149 |
| September 30, 2014 | 0.0461 |
| June 30, 2014 | 0.054 |
| March 31, 2014 | 0.1754 |
| December 31, 2013 | -0.1618 |
| September 30, 2013 | -0.5823 |
| June 30, 2013 | |
| March 31, 2013 | |
| December 31, 2012 | -0.4868 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-143.82
Minimum
Jun 2022
30.11
Maximum
Dec 2022
-4.839
Average
0.5555
Median
Mar 2020
Debt to Equity Ratio Benchmarks
| AbbVie Inc | 5.732 |
| Alnylam Pharmaceuticals Inc | -4.626 |
| Ionis Pharmaceuticals Inc | 3.317 |
| Madrigal Pharmaceuticals Inc | -- |
| Vertex Pharmaceuticals Inc | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 478.45M |
| Total Liabilities (Quarterly) | 630.06M |
| Shareholders Equity (Quarterly) | -151.60M |
| Current Ratio | 3.798 |
| Net Debt Paydown Yield | -1.30% |